《JAMA,3月13日,What Does the Coronavirus Disease 2019 (COVID-19) Mean for Families?》

  • 来源专题:COVID-19科研动态监测
  • 编译者: xuwenwhlib
  • 发布时间:2020-03-14
  • What Does the Coronavirus Disease 2019 (COVID-19) Mean for Families?

    Lindsay A. Thompson, MD, MS1,2; Sonja A. Rasmussen, MD, MS1,3

    JAMA Pediatr. Published online March 13, 2020. doi:10.1001/jamapediatrics.2020.0828

    A new viral illness called coronavirus disease 2019 (COVID-19) was discovered in China in December 2019.

    Lessons learned from China and similar viral diseases can help families prepare for spread in the US. How children in the US will be affected is still mostly unknown. So far, proportionately fewer children have gotten sick in China, and the effects on them have mostly been mild. It is important for families to prepare for spread in the US.

    Who Is at Risk?

    COVID-19 appears to be spread via respiratory secretions when infected people cough or sneeze, similar to how influenza (flu) spreads. Currently, people at risk for COVID-19 include those who have been in close contact with infected people within 14 days before their symptoms began. The average time from when persons are exposed to signs of illness is about 5 days and can range from 2 to 14 days. People with COVID-19 have fever, cough, muscle aches, headache, and diarrhea, which are all symptoms similar to other viral infections, such as the flu. People who need hospitalization usually have severe pneumonia. Currently, there are no treatments or vaccines available.

  • 原文来源:https://jamanetwork.com/journals/jamapediatrics/fullarticle/2763176?resultClick=1
相关报告
  • 《LANCET,3月27日,Understanding COVID-19: what does viral RNA load really mean?》

    • 来源专题:COVID-19科研动态监测
    • 编译者:zhangmin
    • 发布时间:2020-03-28
    • Understanding COVID-19: what does viral RNA load really mean? Gavin M Joynt William KK Wu Published:March 27, 2020DOI:https://doi.org/10.1016/S1473-3099(20)30237-1 In The Lancet Infectious Diseases, Francois-Xavier Lescure and colleagues1 describe the first cases of coronavirus disease 2019 (COVID-19) in Europe, which were reported in France. The detailed clinical features of five patients with COVID-19 are aligned with the quantitative severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral RNA load from nasopharyngeal and other selected sampling sites. Previous studies in patients with SARS, Middle East respiratory syndrome (MERS), and COVID-19 generally provide insufficient detail to allow examination of the relationship between individual patient clinical course and viral RNA load.
  • 《JAMA,4月3日,Coronavirus Disease 2019 (COVID-19) Infection and Renin Angiotensin System Blockers》

    • 来源专题:COVID-19科研动态监测
    • 编译者:zhangmin
    • 发布时间:2020-04-06
    • Coronavirus Disease 2019 (COVID-19) Infection and Renin Angiotensin System Blockers Chirag Bavishi, MD, MPH1; Thomas M. Maddox, MD, MSc2,3; Franz H. Messerli, MD4,5,6 Author Affiliations Article Information JAMA Cardiol. Published online April 3, 2020. doi:10.1001/jamacardio.2020.1282 The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has already surpassed the combined mortality inflicted by the severe acute respiratory syndrome (SARS) epidemic of 2002 and 2003 and the Middle East respiratory syndrome (MERS) epidemic of 2013. The pandemic is spreading at an exponential rate, with millions of people across the globe at risk of contracting SARS-CoV-2. Initial reports suggest that hypertension, diabetes, and cardiovascular diseases were the most frequent comorbidities in affected patients, and case fatality rates tended to be high in these individuals. In the largest Chinese study to date,1 which included 44?672 confirmed cases, preexisting comorbidities that had high mortality rates included cardiovascular disease (10.5%), diabetes (7.3%), and hypertension (6.0%). Patients with such comorbidities are commonly treated with renin angiotensin system blockers, such as angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs).